Belimumab (Benlysta) is a prescription medicine used to treat adults with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. It is a monoclonal antibody that works by targeting and blocking a specific protein called B-lymphocyte stimulator (BLyS) that is involved in the overactivity of the immune system. Belimumab is used to reduce the signs and symptoms of SLE, including joint pain, fatigue, and rash.
Belimumab, sold under the brand name Benlysta, is a medication used to treat systemic lupus erythematosus (SLE), also known as lupus. Here's a detailed description of its key characteristics:
Purpose:
- Belimumab is primarily used to treat adults with active, autoantibody-positive SLE who are experiencing high disease activity despite standard therapy.
- SLE is a chronic autoimmune disease that causes the immune system to attack healthy tissues and organs.
- "Autoantibody-positive" indicates the presence of specific antibodies in the blood that target the body's own tissues, contributing to the inflammatory processes in SLE.
- "High disease activity" refers to a more severe form of SLE with significant inflammation and potential organ involvement.
Mechanism of Action:
- Belimumab works by blocking the activity of a protein called B-lymphocyte stimulator (BLyS). BLyS plays a role in the survival and development of B cells, a type of white blood cell involved in antibody production.
- By blocking BLyS, belimumab helps to reduce the lifespan of B cells and decrease the production of certain autoantibodies that contribute to inflammation and tissue damage in SLE.
Administration:
- Belimumab is administered intravenously (IV) by a healthcare professional in a hospital or medical facility, typically once a month.
- The dosage may be adjusted based on individual factors like weight and response to the medication.
Important Considerations:
- Belimumab can cause side effects, including:
- Upper respiratory tract infections: Increased susceptibility to infections due to the modulation of the immune system.
- Infusion-related reactions: These can include fever, chills, headache, and nausea, usually mild and manageable.
- Headache, fatigue, and diarrhea: These are generally mild and improve over time.
- Belimumab is not a cure for SLE but may help control disease activity, reduce flares, and improve symptoms.
- It is important to consult with a healthcare professional to determine if belimumab is the right treatment option for you, considering your individual health history and the severity of your SLE.
Overall:
Belimumab offers a novel approach to treating active SLE in adults by targeting B cells and their role in autoantibody production. While it can help manage the disease and improve symptoms, it is crucial to be aware of potential side effects and to consult with a healthcare professional for personalized treatment recommendations.